Norges Bank bought a new stake in IQVIA Holdings Inc. (NYSE:IQV – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,206,846 shares of the medical research company’s stock, valued at approximately $497,445,000. Norges Bank owned about 1.30% of IQVIA at the end of the most recent quarter.
Other institutional investors also recently modified their holdings of the company. Ameliora Wealth Management Ltd. bought a new position in shares of IQVIA in the fourth quarter valued at about $25,000. Physician Wealth Advisors Inc. raised its holdings in shares of IQVIA by 1,340.0% in the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after buying an additional 134 shares during the last quarter. International Assets Investment Management LLC bought a new position in shares of IQVIA in the fourth quarter valued at about $27,000. Westside Investment Management Inc. raised its holdings in shares of IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after buying an additional 101 shares during the last quarter. Finally, Measured Wealth Private Client Group LLC bought a new position in shares of IQVIA in the third quarter valued at about $30,000. Institutional investors own 89.62% of the company’s stock.
Analyst Ratings Changes
IQV has been the subject of a number of research analyst reports. Jefferies Financial Group cut their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 6th. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Sunday, April 19th. Royal Bank Of Canada assumed coverage on shares of IQVIA in a research report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price objective for the company. BMO Capital Markets set a $250.00 price objective on shares of IQVIA in a research report on Friday, February 6th. Finally, Barclays upgraded shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective for the company in a research report on Friday, March 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $225.69.
IQVIA Stock Performance
Shares of NYSE:IQV opened at $182.03 on Monday. The stock has a market capitalization of $30.38 billion, a P/E ratio of 22.56, a P/E/G ratio of 1.74 and a beta of 1.21. IQVIA Holdings Inc. has a 1-year low of $136.41 and a 1-year high of $247.04. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The business has a 50-day moving average price of $170.34 and a two-hundred day moving average price of $196.05.
IQVIA (NYSE:IQV – Get Free Report) last issued its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. The company had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.
IQVIA announced that its Board of Directors has approved a stock repurchase plan on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board believes its stock is undervalued.
IQVIA Company Profile
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Featured Stories
- Five stocks we like better than IQVIA
- These 3 CLO ETFs Target a Niche Corner of the Fixed-Income Market
- 3 Ways to Play the Data Center Land Grab
- The Smarter Way to Invest in AI Without Taking Extreme Risk
- 3 Dividend Kings That Earn Their Crown Every Quarter
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
